Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Infliximab vs purine analogues

Serious adverse events (at 2 years) · Participants with Crohn's disease in remission

It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.79 [0.37, 1.68]
1 study · 140 participants
Very low

Infliximab combined with purine analogues vs purine analogues

Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission

It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 1.19 [0.54, 2.64]
2 studies · 257 participants
Very low